A Bayesian Bridging Model Using Phase 3 Data in Treatment-Experienced HCV Genotype 3 Patients Demonstrates Extending Sofosbuvir plus Ribavirin Treatment from 12 to 16 Weeks in Treatment-Naive Genotype 3 Patients May Significantly Increase SVR Rates

被引：0

作者：

Bekele, B. Nebiyou ^{[1
]}

Nelson, David R. ^{[2
]}

Gordon, Stuart C. ^{[3
]}

Feld, Jordan J. ^{[4
]}

Patel, Keyur ^{[5
]}

Lawitz, Eric ^{[6
]}

Sheikh, Aasim M. ^{[7
]}

Brainard, Diana M. ^{[1
]}

Symonds, William T. ^{[1
]}

McHutchison, John G. ^{[1
]}

Mangia, Alessandra ^{[8
]}

Gane, Edward J. ^{[9
]}

机构：

[1] Gilead Sci Inc, Foster City, CA 94404 USA

[2] Univ Florida, Gainesville, FL USA

[3] Henry Ford Hlth Syst, Detroit, MI USA

[4] Univ Toronto, Toronto, ON, Canada

[5] Duke Univ, Durham, NC USA

[6] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA

[7] GI Specialists GA, Marietta, GA USA

[8] Casa Sollievo della Sofferenza Hosp, San Giovanni Rotondo, Italy

[9] Aukland City Hosp, Auckland, New Zealand

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1117

引用

页码：754A / 754A

页数：1